Market Place
Sourcing Support
Merck`s HIV combo treatment meets efficacy bar in Ph 3 trials
20 Dec 2024 //
FIERCE BIOTECH
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
22 Oct 2024 //
FIERCE BIOTECH
Merck-Gilead`s weekly HIV combo maintains viral suppression
07 Mar 2024 //
FIERCE BIOTECH
Merck Opens Enrollment in PIII with Islatravir in Combination with Doravirine
22 Feb 2023 //
BUSINESSWIRE
Merck’s HIV pipeline shifts as islatravir PrEP program is discontinued
29 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
Merck to start studying lower dose of HIV drug after FDA hold
21 Sep 2022 //
REUTERS
FDA pauses several trials of Merck’s investigational HIV drug
16 Dec 2021 //
PHARMAFILE
FDA grounds Merck & Co.`s islatravir programme in HIV
14 Dec 2021 //
REUTERS
U.S. FDA puts Merck’s HIV drug trials on hold
13 Dec 2021 //
FXEMPIRE
Merck Puts Clinical Holds on Studies Evaluating Islatravir for HIV-1 Infection
13 Dec 2021 //
BUSINESSWIRE
Merck pauses 2 more trials of backbone HIV drug over red flag
08 Dec 2021 //
FIERCEBIOTECH
Gilead and Merck Pause Enrollment for Phase 2 HIV Study Evaluating Islatravir
24 Nov 2021 //
TRIALSITENEWS
Merck Provides Update on Phase 2 Trial of MK-8507+Islatravir for HIV-1
18 Nov 2021 //
BUSINESSWIRE
Merck HIV combo pill compares to existing meds in phase 3 trials
28 Oct 2021 //
FIERCEBIOTECH
Merck`s islatravir hits with a PhIII combo win; FDA filing plans
26 Oct 2021 //
ENDPTS
PrEP updates and new products at IAS 2021
08 Sep 2021 //
WHO
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.